對抗 COVID19
23.81k 個跟隨者 • 14 個股票代號 追蹤清單由 TREA 提供
跟隨此名單即可探索和追蹤具有 COVID-19 相關治療和保健計劃之上市公司的股票。
策劃人： TREA
表現
| 追蹤清單 | 今日股價變化 | 1 個月回報 | 1 年回報 | 總回報 |
|---|---|---|---|---|
| 對抗 COVID19 | - | - | - | - |
| ^GSPC | -0.22% | -3.23% | +20.62% | +5288.30% |
14 個股票代號
| 代號 | 公司名稱 | 收市價 | 變化 | % 變化 | 市場時間 | 成交量 | 平均成交量 (3 個月) | 市值 |
|---|---|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 145.74 | +0.97 | +0.67% | 下午4:00 [EDT] | 9.34M | 7.45M | 351.20B |
| ABBV | AbbVie Inc. | 164.66 | +0.41 | +0.25% | 下午4:00 [EDT] | 4.48M | 5.64M | 291.56B |
| PFE | Pfizer Inc. | 25.39 | -0.03 | -0.12% | 下午4:00 [EDT] | 35.46M | 42.90M | 143.77B |
| SNY | Sanofi | 45.39 | -0.72 | -1.56% | 下午4:00 [EDT] | 4.35M | 1.96M | 113.31B |
| REGN | Regeneron Pharmaceuticals, Inc. | 893.99 | -7.20 | -0.80% | 下午4:00 [EDT] | 446.33k | 469.58k | 98.13B |
| GILD | Gilead Sciences, Inc. | 66.16 | -0.77 | -1.15% | 下午4:00 [EDT] | 6.39M | 7.42M | 82.50B |
| GSK | GSK plc | 39.27 | -0.33 | -0.83% | 下午4:00 [EDT] | 2.13M | 3.59M | 81.22B |
| TAK | Takeda Pharmaceutical Company Limited | 13.16 | +0.01 | +0.08% | 下午4:00 [EDT] | 1.29M | 1.87M | 41.29B |
| MRNA | Moderna, Inc. | 102 | -1.44 | -1.39% | 下午4:00 [EDT] | 1.74M | 3.78M | 39.05B |
| BNTX | BioNTech SE | 86.17 | -0.23 | -0.27% | 下午4:00 [EDT] | 567.94k | 626.49k | 20.77B |
| VIR | Vir Biotechnology, Inc. | 7.96 | -0.29 | -3.52% | 下午4:00 [EDT] | 832.34k | 1.08M | 1.07B |
| NVAX | Novavax, Inc. | 3.89 | - | - | 下午4:00 [EDT] | 2.85M | 7.43M | 544.42M |
| INO | Inovio Pharmaceuticals, Inc. | 10.2 | -0.87 | -7.86% | 下午4:00 [EDT] | 394.03k | 499.67k | 238.38M |
Business WireU.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
OSAKA, Japan & CAMBRIDGE, Mass., April 18, 2024--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn’s disease (CD) after induction therapy with intravenous (IV) ENTYVIO.1 The subcutaneous administration of ENTYVIO was also approved by FDA in September 2023 for the maintenance treatment of adults with moderately to
- Reuters
US FDA mandates label updates on CAR-T cancer therapies
The U.S. Food and Drug Administration said on Thursday cancer therapies that use CAR-T technology will require changes to the so-called "boxed warning" to highlight the serious risk of T-cell blood cancer in patients who use these therapies. The health regulor has required related updates to other sections of the label such as warnings and precautions, postmarketing experience, patient counseling information and medication guide. In January, the FDA asked a host of drugmakers including Gilead Sciences, Johnson & Johnson and Novartis to add a boxed warning to their CAR-T cancer therapies, as it received reports of patients developing a type of T-cell blood cancer after being treated with them.
ZacksGilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Gilead Sciences (GILD) closed at $66.16 in the latest trading session, marking a -1.15% move from the prior day.
